SH2 domain binding inhibitors

Details SH2 domain binding inhibitors SH2 domain binding inhibitors

2003-06-26

2008-09-16

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S317000, C530S333000

Reexamination Certificate

active

07425537

ABSTRACT:
Disclosed are compounds for SH2 domain binding inhibition, for example, a compound of formula (I), wherein R1is a lipophile; R2, in combination with the phenyl ring, is a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. The conformationally compounds provide enhanced binding affinity with SH2 domain protein. Also disclosed are a pharmaceutical compositions and a method for inhibiting an SH2 domain from binding with a phosphoprotein.

REFERENCES:
patent: 3906031 (1975-09-01), Carpino et al.
patent: 4394519 (1983-07-01), Carpino et al.
patent: 4598087 (1986-07-01), Horwell
patent: 4879398 (1989-11-01), Getman et al.
patent: 4885316 (1989-12-01), Rothgery et al.
patent: 5132409 (1992-07-01), Felder et al.
patent: 5182263 (1993-01-01), Danho et al.
patent: 5200546 (1993-04-01), Burke, Jr. et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5296608 (1994-03-01), Danho et al.
patent: 5304552 (1994-04-01), Hanson
patent: 5369110 (1994-11-01), Schmidlin et al.
patent: 5457111 (1995-10-01), Luly et al.
patent: 5457114 (1995-10-01), Stüber et al.
patent: 5463062 (1995-10-01), Hemmerle et al.
patent: 5475129 (1995-12-01), Burke, Jr. et al.
patent: 5491253 (1996-02-01), Stuk et al.
patent: 5508437 (1996-04-01), Danho et al.
patent: 5525733 (1996-06-01), Novack et al.
patent: 5554749 (1996-09-01), Wallace et al.
patent: 5580979 (1996-12-01), Bachovchin
patent: 5587372 (1996-12-01), Aszodi et al.
patent: 5612370 (1997-03-01), Atwal
patent: 5616776 (1997-04-01), Stuk et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5627283 (1997-05-01), Stüber et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5676923 (1997-10-01), Platzek et al.
patent: 5679842 (1997-10-01), Kleiner
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5688992 (1997-11-01), Burke, Jr. et al.
patent: 5698731 (1997-12-01), Bosetti et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5710173 (1998-01-01), Tang et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5714361 (1998-02-01), Widlanski
patent: 5721361 (1998-02-01), Lennon et al.
patent: 5741777 (1998-04-01), Grinnell et al.
patent: 5753687 (1998-05-01), Mjalli et al.
patent: 5756817 (1998-05-01), Choi et al.
patent: 5773411 (1998-06-01), Wells et al.
patent: 5780496 (1998-07-01), Tang et al.
patent: 5786454 (1998-07-01), Waksman et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5843997 (1998-12-01), Heinz et al.
patent: 5847135 (1998-12-01), Bemis et al.
patent: 5849693 (1998-12-01), Wells et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5859002 (1999-01-01), Kalish et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886195 (1999-03-01), Tang et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5916749 (1999-06-01), Bandman et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5936084 (1999-08-01), Jirousek et al.
patent: 5952320 (1999-09-01), Davidsen et al.
patent: 5958957 (1999-09-01), Andersen et al.
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 5981569 (1999-11-01), App et al.
patent: 6037134 (2000-03-01), Margolis
patent: 6127391 (2000-10-01), Hansen et al.
patent: 6136542 (2000-10-01), Demers et al.
patent: 6180619 (2001-01-01), Kim
patent: 6228986 (2001-05-01), Lanter et al.
patent: 6307090 (2001-10-01), Burke, Jr. et al.
patent: 6545038 (2003-04-01), De et al.
patent: 6977241 (2005-12-01), Burke et al.
patent: WO 94/07913 (1994-04-01), None
patent: WO 95/11917 (1995-05-01), None
patent: WO 96/23813 (1996-08-01), None
patent: WO 97/08193 (1997-03-01), None
patent: WO 97/12903 (1997-04-01), None
patent: WO 98/17683 (1998-04-01), None
patent: WO 00/56760 (2000-09-01), None
patent: WO 00/73326 (2000-12-01), None
patent: WO 01/28577 (2001-04-01), None
patent: WO 01/30325 (2001-05-01), None
patent: WO 02/16407 (2002-02-01), None
patent: WO 02/20525 (2002-03-01), None
patent: WO 02/40684 (2002-05-01), None
patent: WO 02/056837 (2002-07-01), None
T Gura. Science (1997) 278, pp. 1041-1042.
R McKie. The Observer (2001). 4 pages.
C Gorman, et al. Time (May 18, 1998) 151, 9 Pages.
GB Dermer. Bio/Technology (1994) p. 320.
Ye et al., “L-O-(2-Malonyl)tyrosine” A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides, J. Med. Chem. vol. 38, pp. 4270-4275, 1995.
Burke, Jr., et al., “4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides”, J. Med. Chem., vol. 39, pp. 1021-1027, Mar. 1, 1996.
Schoepfer et al., “Structure-based Design of Peptidomimetic Ligands of Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 8, pp. 2865-2870, 1998.
Yao et al., “Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands”, J. Med. Chem., vol. 42, pp. 25-35, 1999.
Gay et al., “Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility”, The Journal of Biological Chemistry, vol. 274, pp. 23311-23315, Aug. 13, 1999.
Schoepfer et al., “Highly Potent Inhibitors of the Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 9, pp. 221-226, 1999.
Burke, Jr., et al., Monocarboxylic-Based Phosphotyrosyl Mimetics in the Design of Grb2 SH2 Domain Inhibitors, Bioorganic & Medicinal Chemistry Letters 9, pp. 347-352, 1999.
Gilmer et al., “Peptide Inhibitors of src SH-3-SH2-Phosphorprotein Interactions”, The Journal of Biological Chemistry, vol. 269, pp. 31711-31719, Dec. 16, 1994.
Charifson et al., “Peptide Ligands of pp60c-srcSH2 Domains: A Thermodynamic and Structural Study”, Biochemistry, vol. 36, pp. 6283-6293, 1997.
Liu et al., “Synthesis of L-2,3,5,6-Tetrafluoro-4-(Phosphonomethyl) Phenylalanine, a Novel Non-Hydrolyzable Phosphotyrosine Mimetic and L-4-(Phosphonodifluoromethyl)Phenylalanine”, Tetrahedron Letters, vol. 38, pp. 1389-1392, 1997.
Cleland, “The Meerwein Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Anilines”, The Journal of Organic Chemistry, Vo., 34, pp. 744-747, Mar. 1969.
Gao et al., Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic, J. Med. Chem., vol. 43, pp. 911-920, 2000.
Furet et al., Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain, J. Med. Chem., vol. 41, pp. 3442-3449, 1998.
Tong et al., “Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding”, The Journal of Biological Chemistry, vol. 273, pp. 20238-20242 Aug. 7, 1998.
Kim et al.,FEBS Lett, 453, 174-178, 1999.
Tulasne et al., “The Multisubstrate Docketing Site of the MET Receptor is Dispensable for MET-mediated RAS Signaling and Cell Scattering”, Molecular Biology of the Cell, vol. 10, pp. 551-565, Mar. 1999.
Kim et al., “Dual Signaling Role of the Protein Tyrosine Phosphotase SHP-2 in Regulating Expression of Acute-Phase Plasma Proteins by Interleukin-6 Cytokine Receptors in Hepatic Cells”, Molecular and Cellular Biology, vol. 19, pp. 5326-5338, Aug. 1999.
Nguyen et al., “Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires

Affiliated with

Also associated with

Rating

SH2 domain binding inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SH2 domain binding inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SH2 domain binding inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3989197